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Abstract. The mechanisms associated with aldosterone pro-
duction both systemically and locally as well as the effects of
aldosterone blockade on the pathophysiology of heart fail-
ure (HF) have been extensively reviewed in this series and
elsewhere. This article will review the clinical evidence sup-
porting the use of aldosterone blocking agents (AB)in pa-
tients with HF and speculate on some potential future uses.
Results of Major Clinical Trials of AB
in Patients with HF
The randomized Aldosterone evaluation study
(RALES) [1] was the first study to show the ben-
efit of AB on mortality as well as hospitalization
for HF. In Rales over 1600 patients with a his-
tory of severe HF (NYHA class IV within the 6
months prior to entry into the study) who were
in NYHA class III-IV and maintained on stan-
dard therapy including an angiotensin converting
enzyme—inhibitor (ACE-I), beta blocker (BB), di-
uretic, and digoxin were randomized to the AB
spironolactone 25–50 mg/day or placebo with the
primary endpoint of total mortality. Patients en-
tered into the study had to have evidence of sys-
tolic left ventricular dysfunction (SLVD) with a
left ventricular ejection fraction (LVEF) ≤35%.
The study was stopped prematurely at a mean
followup of 2 years when it was found that pa-
tients randomized to the AB strategy had a sig-
nificant 30% reduction in total mortality as well
as a 35% reduction in the incidence of hospitaliza-
tion for HF. The reduction in total mortality was
due both to a reduction in death due to progres-
sive HF and sudden cardiac death. These benefits
were relatively uniform across a number of prede-
termined subgroups including age, gender, etiol-
ogy of HF, and whether or not the patient was on
an ACE-I, BB, diuretic, or digoxin. Initially there
was some reluctance to apply the results of this
study to clinical practice since only 10–11% of pa-
tients were on a BB, in view of the fact that this
study was initiated before the results of the large
scale BB event trials in patients with HF were
known. However, the point estimate for a reduc-
tion in mortality in those patients on a BB was
even greater than in those not on a BB. More im-
portantly the results of the Eplerenone Heart Fail-
ure and Survival study (EPHESUS) [2] of the AB
eplerenone 25–50 mg/day in which 75% of patients
were on a BB and 86–87% on an ACE-I or an-
giotensin receptor blocking agent (ARB) showed
the effectiveness of an AB in reducing mortality
in patients with HF or SLVD post myocardial in-
farction (MI) on both an ACE-I or ARB and a BB.
On the basis of Rales AB is now recommended
for patients with severe HF in both ACC/AHA
and European guidelines and is finding increasing
application.
AB have also been shown to be beneficial in
patients with HF and SLVD early post MI. EPH-
ESUS [2] randomized over 6600 patients between
day 3–14 following an acute MI with a LVEF ≤40%
and clinical signs of HF, unless they had diabetes
mellitus in which case only a LVEF ≤40% was re-
quired, to usual care or eplerenone 25 mg/day up-
titrated to 50 mg/day at 1 month if there was no
evidence of hyperkalemia (potassium >5.0 meq/l).
Over 85% of patients were on an ACE-I or an ARB
and 75% on a BB. Slightly less than half the pa-
tients were on statin and had undergone coronary
reperfusion. The mean time from onset of infarc-
tion to randomization was 7.3 days and the mean
LVEF 33%. However, the actual LVEF at the time
of randomization was likely considerably greater
than 33% since the LVEF was determined at any
time from the onset of MI to randomization by
which time many patients had recovered from ven-
tricular stunning, hibernation, and or had under-
gone coronary reperfusion.
At a mean follow up of 16 months patients ran-
domized to eplerenone had a significant 15% re-
duction in total mortality and a 13% reduction in
the coprimary endpoint of CVmortality/CV hos-
pitalization. The major cause of cardiovascular
death in Ephesus was sudden cardiac death which
was significantly reduced by 21%. In a retrospec-
tive analysis of those patients with a LVEF ≤30%
at baseline there was a 33% reduction in sud-
den cardiac death. Of importance was the finding
that at 30 days post randomization (a mean of 37
days post MI) there was a significant 31% reduc-
tion in total mortality. The finding of a significant
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reduction in total mortality in these patients has
important implications since patients with HF
and or SLVD post MI have a greatly increased risk
of mortality, mainly due to sudden cardiac death,
within the first 30 days post MI despite treatment
with an ACE-I and a BB. Early implantation of an
automatic implantable defibrillator (AICD) would
appear to be a useful strategy in these high risk in-
dividuals. However the DYNAMIT [3] study which
randomized patients with an acute MI between
day 6 to 40 post MI with a LVEF ≤35% found that
those patients randomized to the AICD strategy
had an increase in total mortality at 1 year due
to an excess in non-sudden deaths. The Madit 2
trial did show a significant reduction in total mor-
tality in patients with a LVEF ≤30% randomized
to a usual care or AICD strategy >30 days post
MI [4]. However, benefit in that study was nor evi-
dent until almost 1 year post randomization. Thus,
it has been suggested that eplerenone could be an
important bridging strategy which could prevent
ventricular remodeling and therefore decrease the
number of patients with an LVEF ≤30% at 30 days
post MI and in those patients with a persistent
LVEF ≤30% reduce early mortality such that they
would be alive to benefit from 0the long term ben-
eficial effects of AICD implantation. Although in
EPHESUS [2] eplerenone was given at a mean of
7.3 days post MI a subsequent study by Hyashi
et al. [5] in patients with their first anterior MI the
AB canreonate was administered iv on day 1 post
MI after primary percutaneous coronary revascu-
larization and followed by oral spironolactone for
1 month in a randomized protocol. In that study
AB was shown to significantly prevent ventricular
remodeling and collagen formation at 1 month. Al-
though there has not been a large scale event trial
of an AB administered on day 1 post MI it would
seem most efficacious given the results of EPH-
ESUS [2] and that of Hyashi et al. [5] to adminis-
ter an AB as soon as possible post MI in patients
with evidence of HF and or SLVD to impact the
relatively high mortality in these individuals. On
the basis of the EPHESUS [2] study administra-
tion of an AB is now a class I indication post MI in
patients with HF and SLVD post MI. It is however
likely that AB will also be effective in reducing car-
diovascular events in patients without evidence of
HF or an LVEF ≤40% post MI, in that the mean
LVEF at baseline in the study of Hyashi et al. [5]
was approxamitely 47% and patients were not re-
quired to have evidence of HF.
Both in RALES [1] and EPHESUS [2] there
was an increase in the incidence of serious hyper-
kalemia (K ≥ 6.0 meq/l). However the risk was
relatively small and no patient in RALES [1] or
EPHESUS [2] randomized to an AB had a death
attributable to hyperkalemia.
Patient Monitoring of Serum Potassium in
Patients with HF Treated with an AB
On the basis of the experience in RALES [1] and
EPHESUS [2] one should obtain a serum potas-
sium and calculate creatinine clearance before
beginning an AB. Patients with a serum K >
5.0 meq/l and or those with severe renal dysfunc-
tion (Creatinine clearance ≤30 ml/min) in gen-
eral should not receive an AB. After instituting an
AB serum potassium should be determined at 1
week, 1 month, and then every 3–6 months there-
after. In patients with moderate renal dysfunc-
tion and a creatinine clearance <60–>30 ml/min
it might be prudent to monitor serum potassium
weekly for the first month and then monthly there-
after for the first several months. This sequence
should be repeated every time the dose of the AB
is increased, when there is a change in fluid bal-
ance such as vomiting or diarrhea, and or when
there is a change in medication which could effect
potassium excretion such as a non steroidal anti-
inflammatory agent.
If at any time serum potassium is ≥5.5 meq/l
the dose of the AB should be reduced by half and
serum potassium monitored weekly until serum
potassium is <5.5 meq/l. If at any time serum
potassium is ≥6.0 meq/l on a non hemolyzed sam-
ple a careful review of concomitant medication
should be undertaken and if there is no precip-
itating factor such as the use of a non steroidal
anti-inflammatory agent or Cox-2 inhibitor the AB
should be discontinued and not restarted until the
serum potassium is <5.0 meq/l and or any pre-
cipitating factor is eliminated. If spironolactone
is chosen the initial dose should be 25 mg/day
as in RALES [1]. However, in elderly patients
(>75 years),those with diabetes mellitus and evi-
dence of microalbuminuria, and or those with com-
promised renal function it might be prudent to be-
gin dosing with 25 mg every other day. If after
1 month there is no increase in serum potassium
>5.0 meq/l the dose of spironolactone could be in-
creased to 25 mg daily. In patients with evidence
of progressive HF and or in those patients with
diuretic resistance higher doses of spironolactone
up to 200 mg/day have been shown to be effective
in causing diuresis. Once diuresis is achieved it
might however be prudent to reduce the dose to
25–50 mg/day. If eplerenone is chosen the starting
dose is 25 mg/day, which is relatively lower than
25 mg of spironolactone. If after 1 month there
is no evidence of hyperkalemia the dose should
be increased to 50 mg/day. In contrast to spirono-
lactone there is however no significant experience
with higher doses of eplerenone in patients with
diuretic resistance, although 50 mg twice daily is
approved for use in patients with hypertension.
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Which AB Should One Use in a Patient
with HF?
Both spironolactone and eplerenone are effective
inhibitors of the minerallocorticoid receptor (MR).
While there are no definitive comparative trials in
patients with HF there is data to reach at least a
provisional answer in regard to the choice of one
or the other in particular circumstances. A major
difference between spironolactone and eplerenone
relates to their specificity for the MR. Spironolac-
tone is less specific for the MR than eplerenone and
down regulates androgen receptors while upregu-
lating progesterone receptors [6]. Spironolactones
use is therefore associated with gynechomastia,
breast pain and impotence in males as well as
menstrual irregularities and libido changes in pre-
menstrual females. In EPHESUS [2] there was
no evidence of an increase in any of these sexu-
ally related side effects known to be associated
with the use of spironolactone in over 3300 pa-
tients followed on eplerenone for a mean of 16
months, attesting to its relative selectivity for the
MR. Spironolactone also has a relatively long half
life of over 24 hours due to its metabolite potas-
sium canreonate in contrast to eplerenone which
has a relatively shorter half life [7]. This difference
in half life could impact the relative incidence of
serious hyperkalemia. Although there have been
no adequately powered comparative studies one
would predict that the incidence of serious hy-
perkalemia would be less with eplerenone than
sprionolactone. Spironolactone also is known to
increase serum digoxin levels while eplerenone
does not. Another difference is cost. Spironolac-
tone is generic and cost less than $1 per day in
comparison to eplerenone which was recently in-
troduced into clinical practice and costs over $3 per
day. Thus in males, premenstrual females, and in
those with compromised renal function one might
therefore favor the use of eplerenone. In post
menopausal females with normal renal function
spironolactone might be preferred due to cost. If
cost is the overrding issue and the patient can not
afford eplerenone I would recommend spironolac-
tone in males, premenstrual females and in those
with compromised renal function rather than do-
ing without an AB. It should however be empha-
sized that these recommendations are provisional
and await more definitive information from direct
comparative trials.
Which Patients with HF and SLVD Should
be Treated with an AB?
Patients with severe or progressive HF and SLVD
both due to ischemic and non ischemic heart dis-
ease should be treated with an AB in addition to
an ACE-I, BB, diuretic +/− digoxin based upon
the results of RALES [1]. Similarly, patients with
HF and SLVD post MI should be given an AB as
early as possible post MI based upon the results of
EPHESUS [2] and the AB continued indefinitely
in those with persistent SLVD and or evidence of
HF.
The situation in patients with mild heart fail-
ure and SLVD is less clear as there have as
yet been no definitive trials addressing mortal-
ity/hospitalization for HF in this situation. In
these patients one might chose an ARB to add to
an ACE-I and a BB. The use of an ARB could be
justified on the basis of the Charm-added trail [8]
in which the addition of candesartan 32 mg/day
to standard therapy including an ACE-I and BB
significantly reduced CV mortality/hospitalization
for HF. However in Valheft [9], in a similar popu-
lation, valsartan 160 mg twice daily did not have
a beneficial effect on mortality in patients treated
with both an ACE-I and a BB. There was however
a significant reduction in hospitalization for HF
with valsartan, but even this effect was lost in pa-
tients who achieved target doses of their ACE-I.
In patients with HF and or SLVD early post
MI valsartan was shown to be equivalent in ef-
fectiveness to the ACE-I captopril [10]. However
there was no benefit of adding valsartan to cap-
topril.Thus the efficacy of adding an ARB to an
ACE-I and a BB both in patients with chronic
HF due to SLVD and in patients with HF and or
SLVD early post MI is uncertain. While there is
no large scale randomized study evaluating the
use of an AB in patients with mild HF due to
SLVD there have been several small randomized
studies evaluating surrogate endpoints [11–14].
These studies suggest that the addition of an AB
to standard therapy including an ACE-I and a BB
improves these endpoints including ventricular
remodeling, collagen formation, endothelial func-
tion, heart rate variability, baroreceptor function,
ventricular ectopic activity, and exercise perfor-
mance. While there may be some benefit of adding
an ARB to an ACE-I in preventing the production
of ATII and or in preventing stimulation of the
AT1 receptor there is an equal or better rationale
for adding an AB. Although ATII is a potent stim-
ulus for the production of ATII other stimuli such
as potassium are also important. For example, in
the angiotensinogen knock out mouse, in which
ATII is not present, aldosterone production from
the adrenal gland can be obtained by modulat-
ing serum sodium [15]. Further, while both ATII
and aldosterone share common signaling path-
ways through the epidermal derived growth factor
receptor (EDGFR) they also have independent sig-
naling pathways, suggesting that optimum bene-
fit will be obtained by blocking or inhibiting both
ATII and aldosterone [16]. Experimental studies
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have shown a significantly better effect on ventric-
ular remodeling post MI when an ACE-I is com-
bined with an AB in comparison to either alone
[17]. Further prospective randomized studies in
patients with chronic HF due to SLVD comparing
the strategy of adding an ARB, an AB, or both to an
ACE-I and a BB will however be required before
any final conclusion can be reached.
Future Application of AB in Patients
with HF
The use of an AB in patients with asymptomatic
SLVD has not been studied. ACE-I and BB are ef-
fective in reducing CV risk in these patients. It is
possible, although as yet unproven, that the ad-
dition of an AB in these patients who have sys-
tolic ventricular dysfunction and activation of the
RAAS would provide further benefit.
The role of AB in patients with HF associ-
ated with preserved ventricular function is also
uncertain. Increasing data both in animals and
man does however suggest a beneficial effect of
an AB in this situation. AB has been shown to
regress ventricular hypertrophy, myocardial colla-
gen formation, vascular stiffness,and to improve
endothelial function [18–21]. AB has also been
shown to improve echocardiograpic indicies of
diastolic function in patients with diastolic HF
[20]. The hypothesis that an AB added to stan-
dard therapy will improve clinical outcome (CV
mortality/hospitalization for HF) in patients with
HF associated with preserved ventricular func-
tion is being tested by the NHLBI in a large scale
prospective randomized trial.
There is also reason to postulate that AB will
be beneficial in other forms of HF such as HF
due to valvular heart disease, myocarditis, and
drug induced cardiomyopathy. AB may also have
an important role in the prevention of HF by pre-
venting target organ damage associated with es-
sential hypertension and or diabetes mellitus,as
well as preventing the progression of atherosclero-
sis. Experimental studies have shown that AB de-
creases the production of reactive oxygen spieces
(ROS),possibly related to an improvement in an-
tioxidant reserve through an increase in the en-
zyme glucose 6 phosphatedehydrogenase (G6PD)
with a consequent increase in glutathione [22].
AB has also been shown to improve lipid in-
duced endothelial dysfunction [23], macrophage
oxidized LDL-cholesterol [24], and experimental
atherosclerosis in the apo-e knock out mouse [25].
Clearly although AB has achieved an important
role in the therapy of patients with chronic HF and
SLVD as well as in patients with HF and SLVD
post MI there remains much to be learned about
the clinical application of AB to patients with HF.
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